The "Checkpoint Inhibitor Refractory Cancer Drugs Market – Growth, Share, Opportunities & Competitive Analysis, 2025 – 2032" report has been added to the Credence Research Inc. offering.

Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy1 ...

Initial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026U.S. Food and Drug ...

The "Checkpoint Inhibitor Refractory Cancer Drugs Market - Growth, Share, Opportunities & Competitive Analysis, 2025 - 2032" report has been added to the ...

In this phase 2 study, researchers aimed to evaluate the effectiveness of tyrosine kinase inhibition in relapsed or refractory germ cell tumors.

Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), ...

CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...

Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy Topline data ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients ...

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically ...

Findings from a phase 1/2 trial (NCT04176) presented at the 2025 American Society of Hematology Annual Meeting and Exposition ...